VA NON-PROMOTABLE LIST

The Non-Promotable List is a list of drug or supply items that are not to be promoted or detailed by pharmaceutical sales representatives. Products are added to this list by the Medical Advisory Panel (MAP) and VISN Pharmacist Executives (VPE) Committee. Decisions are based on one or more of the following criteria:

1) The drug or supply has significant potential for inappropriate use;
2) The medication is usually reserved for second or third-line therapy and there is a first line VANF alternative available;
3) The drug or supply is identified to a specific provider group for the purposes of prescription;
4) When promotion includes content on off-label uses considered outside of evidence-based medical practice;
5) The drug is an NME and has not been reviewed for national formulary status, or a decision regarding its national formulary status is pending; or
6) There is evidence that inappropriate promotion has occurred.

- Aducanumab-avwa (Aduhelm)
- Lecanemab-irmb (Leqembi)
- Hydrocodone bitartrate extended-release capsules (Zohydro)
- Hydrocodone bitartrate extended-release tablets (Hysingla)